TLR9 agonists, such as lefitolimod, effectively modulate the TME and induce anti-tumor responses by promoting the infiltration of CD8 T-cells and reprogramming TAMs in the TME (Kapp et al., 2019). This evidence concerns the gene CD8A and neoplasm.